Oncology ASCO 2026: Can a blood test spot cancer early? with Dr Peter... Dr Peter Sasieni, co-investigator for the NHS Galleri trial, discusses advances in population-level blood screening for early cancer detection.
Oncology ASCO 2026: A potential functional cure in endometrial cancer... For GSK, ASCO 2026 was about long-term follow-up data, with new data from ongoing trials of Jemperli and Blenrep.
Oncology ASCO 2026 reshapes oncology trial design The American Society of Clinical Oncology 2026 annual meeting showcased how, across tumour types, new cancer therapies are achieving deeper responses, extending survival and increasingly mo
Oncology ASCO 2026: AbbVie on ADCs, chemotherapy, and the future of o... For years, ADCs have been positioned as an important addition to the oncology toolkit. But, could they eventually replace chemotherapy altogether?
Oncology ASCO 2026: Powerful evidence for the microbiome in oncology,... Can the state of someone’s gut microbiome – the balance of good and bad bacteria in their digestive tract – affect their response to cancer immunother
Patients ASCO 2026: Quality of life, not just quantity, with Dr Harol... Dr Harold Keer, chief medical officer at Taiho Oncology, goes in-depth about why his company places such an emphasis on oral formulations.
News AstraZeneca’s volrustomig hits Phase 3 setback in lung cance... In another blow to its late-stage pipeline, AstraZeneca has pulled the plug on a phase 3 trial of its lung cancer treatment volrustomig.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.